Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064557 | 0.89 | HDAC1 (1.00) | HDAC1HDAC2 | |
| SCHEMBL1079414 | 0.88 | HDAC1 (1.00) | HDAC1HDAC2NR1H4 | |
| SCHEMBL12933547 | 0.88 | HDAC1 (0.80) | HDAC1HDAC2NPC1RAB9APDE4D | |
| SCHEMBL1064299 | 0.85 | HDAC1 (0.77) | HDAC1HDAC2 | |
| SCHEMBL211732 | 0.85 | HDAC1 (0.84) | HDAC1HDAC2 | |
| SCHEMBL1064879 | 0.83 | HDAC1 (0.73) | HDAC1HDAC2NR1H4 | |
| SCHEMBL1060645 | 0.83 | HDAC1 (1.00) | HDAC1HDAC2 | |
| SCHEMBL1067792 | 0.83 | HDAC1 (0.66) | HDAC1HDAC2MEN1NPC1RAB9A | |
| SCHEMBL12933622 | 0.83 | HDAC1 (0.73) | HDAC1HDAC2 | |
| SCHEMBL1065868 | 0.82 | HDAC1 (0.79) | HDAC1HDAC2NPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC2 5/4885KDM4E 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.